FDA Calendar
Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA dates, Advisory Committee and Phase 2 & 3 trial data releases dates are noted. Phase 1 catalysts for small-cap companies only are listed.
Refer to the FDA Calendar Glossary for a list of terms used in the FDA Decision Calendar and the Biotech Historical Catalyst Calendar for completed biotech stock catalysts.
NOTE: LARGE CAP CATALYSTS - generally only Phase 3 catalysts noted in company presentations and/or earnings releases are shown. Only NASDAQ and NYSE stocks are covered. Stocks listed on PINK/OTC exchanges are not covered.
The dates shown are provided by companies. A regulatory event, for example a PDUFA date or Advisory Committee Meeting, will be issued with an exact date by the FDA. However, most clinical release dates (i.e. Phase 1/2/3) are provided in a range format by companies (e.g, mid-2019 or 4Q 2019). Exact dates for clinical data releases are only rarely issued.
Click on the date for the source of the catalyst. Financial data are delayed 15-25 minutes.
Subscribe HERE to ensure you receive your weekly FREE copy of the BioPharmCatalyst Biotech Stock Watch list and/or our daily option of Biotech Stock Price Movers and Pipeline Database updates.
Showing 150
drugs
Ticker
Price
Drug
Stage
Catalyst
| Ticker | Price | Drug | Stage | Catalyst |
|---|---|---|---|---|
| ADMP |
$0.92
-0.07 -6.65%
|
Higher Dose Naloxone Injection
Opioid overdose
|
PDUFA |
10/31/2019 - overdue
PDUFA date October 31, 2019. Company noted as of November 4, 2019 no communication has been received from the FDA.
|
| AGN |
$181.96
+1.12 +0.62%
|
UBROGEPANT
Migraine
|
PDUFA |
4Q 2019
NDA acceptance announced March 11, 2019. PDUFA 4Q 2019. No exact date provided.
|
| KZR |
$2.61
-0.34 -11.53%
|
KZR-616
Lupus
|
Phase 1/2 | |
| AZN |
$47.08
+0.2 +0.43%
|
Anifrolumab
Lupus
|
Phase 3 | |
| UBX |
$6.76
-0.23 -3.36%
|
UBX0101
Osteoarthritis
|
Phase 1b | |
| EIGR |
$10.38
-0.32 -2.99%
|
Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT
Hepatitis delta virus (HDV)
|
Phase 2 | |
| DCPH |
$48.34
-0.25 -0.51%
|
DCC-3014
Solid tumors or hematological malignancies
|
Phase 1 | |
| ALPN |
$2.45
-0.42 -14.68%
|
ALPN-101
Healthy volunteers
|
Phase 1 | |
| JAGX |
$0.99
+0.2 +25.66%
|
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
|
Phase 2 | |
| RHHBY |
$37.49
-0.07 -0.17%
|
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)
|
Phase 2 | |
| AMRN |
$20.94
+4.03 +23.83%
|
Vascepa
High Triglycerides With Mixed Dyslipidemia
|
PDUFA priority review |
Adcom 11/14/2019; PDUFA (est) 12/28/2019
Advisory Committee meeting November 14, 2019. PDUFA date under priority review September 28, 2019 extended to December 28, 2019.
|
| NBRV |
$1.98
-0.02 -1.00%
|
Contepo
Complicated urinary tract infections (cUTI)
|
NDA Filing |
Early 4Q 2019
CRL issued April 30, 2019. NDA resubmission due early 4Q 2019.
|
| CLBS |
$2.26
-0.04 -1.74%
|
CLBS16 (CLBS14-CMD) - ESCaPE-CMD
Coronary microvascular dysfunction (CMD)
|
Phase 2 | |
| EIDX |
$43.29
-1.63 -3.63%
|
AG10 / BBP-265 - open label
ATTR-CM
|
Phase 2 | |
| BBIO |
$27.96
+1.21 +4.52%
|
AG10 / BBP-265 - open label
ATTR-CM
|
Phase 2 | |
| AGRX |
$2.21
+0.07 +3.27%
|
Twirla
Contraceptive patch
|
PDUFA | |
| ADAP |
$0.86
+0.04 +4.71%
|
MAGE-A4 (ADP-A2M4)
Soild tumors
|
Phase 1 | |
| ALNY |
$90.85
-1.6 -1.73%
|
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
|
Phase 3 | |
| MDCO |
$53.39
-1.98 -3.58%
|
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
|
Phase 3 | |
| KNSA |
$6.75
-0.58 -7.91%
|
Rilonacept
Pericarditis
|
Phase 2 | |
| ONCT |
$6.11
+0.03 +0.49%
|
TK216 and vincristine
Relapsed or refractory Ewing sarcoma
|
Phase 1 | |
| XON |
$5.01
-0.52 -9.40%
|
INXN-4001
Heart failure
|
Phase 1 | |
| ALNY |
$90.85
-1.6 -1.73%
|
Inclisiran - ORION-9
Hypercholesterolemia
|
Phase 3 | |
| MDCO |
$53.39
-1.98 -3.58%
|
Inclisiran - ORION-9
Hypercholesterolemia
|
Phase 3 | |
| PIRS |
$3.38
-0.57 -14.43%
|
PRS-343 and atezolizumab (Tecentriq)
HER2-positive solid tumors
|
Phase 1 | |
| VBIV |
$0.57
+0.01 +1.80%
|
VBI-1901
Recurrent glioblastoma multiforme (rGBM)
|
Phase 1/2 | |
| DMPI |
$0.74
+0.01 +2.08%
|
VAL-083
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)
|
Phase 2 | |
| DMPI |
$0.74
+0.01 +2.08%
|
VAL-083
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)
|
Phase 2 | |
| AGIO |
$33.99
+1.56 +4.81%
|
Ivosidenib and Vorasidenib (AG-881)
IDHm low-grade glioma
|
Phase 1 | |
| VERU |
$1.92
-0.07 -3.52%
|
Zuclomiphene citrate
Hot flashes
|
Phase 2 |
Fall 2019
Phase 2 data due fall of 2019.
|
| EVFM |
$5.36
+0.12 +2.29%
|
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
|
Phase 2/3 |
November 2019
Phase 2b data due November 2019.
|
| RVNC |
$15.17
+0.05 +0.33%
|
DAXI (RT002)
Moderate to severe glabellar (frown) lines
|
BLA Filing |
November 2019
BLA filing due November 2019.
|
| YMAB |
$28.55
-0.46 -1.59%
|
Naxitamab
Relapsed/Refractory High-Risk Neuroblastoma
|
BLA Filing |
November 2019
Rolling BLA filing to commence November 2019 and to be completed by 1Q 2020.
|
| APLT |
$15.30
+0.38 +2.55%
|
AT-007
Galactosemia
|
Phase 1 |
Fall 2019
Phase 1 additional data due fall of 2019.
|
| AQST |
$5.74
-0.24 -4.09%
|
Exservan (riluzole) Oral Film
Amyotrophic Lateral Sclerosis
|
PDUFA | |
| AQST |
$5.74
-0.24 -4.09%
|
Libervant - AQST-203
Epileptic seizures
|
NDA Filing |
November 2019
Rolling NDA filing to be completed November 2019.
|
| FLXN |
$15.96
-0.18 -1.12%
|
Zilretta - FX006 repeat
Osteoarthritis of the knee
|
PDUFA |
November/December 2019 est
PDUFA date for sNDA filing delayed. Decision due in the coming weeks - noted November 11, 2019.
|
| IMMU |
$17.40
+0.2 +1.16%
|
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
|
NDA Filing |
Late-November / early December 2019
NDA to be refiled late-November / early December, 2019.
|
| CELG |
$110.00
+0.43 +0.39%
|
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
|
PDUFA | |
| RHHBY |
$37.49
-0.07 -0.17%
|
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
|
PDUFA | |
| ACAD |
$46.33
+1.09 +2.41%
|
Pimavanserin - Harmony
Alzheimer’s disease psychosis
|
Phase 3 | |
| SAVA |
$1.25
-0.01 -0.75%
|
PTI-125
Alzheimer’s disease
|
Phase 2 | |
| EPZM |
$15.03
+0.17 +1.18%
|
Tazemetostat
Follicular lymphoma
|
Phase 2 |
ASH 2019
NDA filing due December 2019. Updated Phase 2 data due at ASH 2019.
|
| PRNB |
$30.99
-0.81 -2.55%
|
PRN1008
Immune thrombocytopenic purpura (ITP)
|
Phase 2 |
ASH 2019
Phase 2 data due at ASH December 2019.
|
| MGTA |
$10.48
-0.32 -2.96%
|
MGTA-145
Healthy volunteers
|
Phase 1 | |
| CELG |
$110.00
+0.43 +0.39%
|
liso-cel (JCAR017) - TRANSCEND NHL-001
r/r B cell non-Hodgkin lymphoma - cancer
|
Phase 1 | |
| FBIO |
$1.63
+0.12 +7.95%
|
MB-107
X-linked Severe Combined Immunodeficiency (XSCID)
|
Phase 1/2 | |
| MBIO |
$2.67
-0.04 -1.48%
|
MB-107
X-linked Severe Combined Immunodeficiency (XSCID)
|
Phase 1/2 | |
| SRRA |
$0.25
-0.01 -2.22%
|
Momelotinib - (Simplify 1)
Myelofibrosis
|
Phase 3 | |
| ATNM |
$0.26
+0.01 +3.96%
|
Iomab-B
Acute myeloid leukemia (AML)
|
Phase 3 | |
| BLUE |
$76.25
+3.29 +4.51%
|
LentiGlobin - HGB-206
Sickle disease
|
Phase 1/2 | |
| MOR |
$26.17
-0.57 -2.13%
|
MOR208 + idelalisib (COSMOS)
Chronic Lymphocytic Leukemia
|
Phase 2 | |
| VSTM |
$1.03
-0.04 -4.17%
|
Duvelisib
Peripheral T-Cell Lymphoma (PTCL)
|
Phase 2 | |
| AUTL |
$11.50
-0.74 -6.05%
|
AUTO3 - (ALEXANDER)
Relapsed or refractory diffuse large B-celllymphoma (DLBCL)
|
Phase 1/2 | |
| TROV |
$1.72
-0.01 -0.58%
|
Onvansertib (PCM-075)
Acute Myeloid Leukemia (AML)
|
Phase 1/2 | |
| AUTL |
$11.50
-0.74 -6.05%
|
AUTO1
Acute lymphoblastic leukemia (ALL)
|
Phase 1/2 | |
| APTO |
$2.47
-0.1 -3.70%
|
APTO-253
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
|
Phase 1b |
ASH December 2019
Phase 1b data due at ASH December 2019.
|
| CRIS |
$1.36
-0.1 -6.85%
|
Fimepinostat (CUDC-907) and venetoclax
Diffuse-large B-cell lymphoma (DLBCL)
|
Phase 1b |
ASH December 2019
Phase 1 safety data due at ASH December 2019.
|
| GWPH |
$109.40
-3.83 -3.38%
|
Epidiolex
Tuberous Sclerosis Complex
|
Phase 3 | |
| CYCC |
$0.39
+0.02 +4.81%
|
CYC065 + venetoclax
Chronic lymphocytic leukemia (CLL)
|
Phase 1 | |
| ONCT |
$6.11
+0.03 +0.49%
|
Cirmtuzumab and ibrutinib
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
|
Phase 1/2 | |
| SGMO |
$9.62
-0.16 -1.64%
|
SB-525
Hemophilia A
|
Phase 1/2 | |
| AZN |
$47.08
+0.2 +0.43%
|
Calquence
1st line - Chronic lymphocytic leukaemia
|
Phase 3 | |
| XLRN |
$44.86
+0.29 +0.65%
|
Luspatercept
Myelofibrosis
|
Phase 2 | |
| CELG |
$110.00
+0.43 +0.39%
|
Luspatercept
Myelofibrosis
|
Phase 2 | |
| ORTX |
$11.67
-0.32 -2.67%
|
OTL-103
Wiskott-Aldrich Syndrome (WAS)
|
Phase 1/2 | |
| TGTX |
$7.57
-0.22 -2.82%
|
Umbralisib + Ublituximab + Venetoclax
Chronic Lymphocytic Leukemia
|
Phase 1/2 | |
| GMAB |
$22.01
-0.15 -0.68%
|
HexaBody-DR5/DR5
Solid tumors
|
Phase 1/2 | |
| MOR |
$26.17
-0.57 -2.13%
|
Tafasitamab - First-MIND
Diffuse Large B-cell Lymphoma
|
Phase 1 | |
| KDMN |
$3.69
+0.7 +23.41%
|
KD025-208
Chronic graft-versus-host disease (cGVHD)
|
Phase 2 |
ASH December 2019
Phase 2 data due to be presented at ASH December 2019.
|
| QURE |
$53.97
+0.23 +0.43%
|
AMT-061
Hemophilia B
|
Phase 2b | |
| AUTL |
$11.50
-0.74 -6.05%
|
AUTO2
Relapsed or refractory multiple myeloma
|
Phase 1/2 | |
| CELG |
$110.00
+0.43 +0.39%
|
Liso-cel (JCAR017) - TRANSCEND CLL-004
Chronic Lymphocytic Leukemia (CLL)
|
Phase 1 | |
| ATNM |
$0.26
+0.01 +3.96%
|
Actimab-A in combination with CLAG-M
Relapsed or refractory acute myeloid leukemia (AML)
|
Phase 1 | |
| PTLA |
$27.68
-0.37 -1.32%
|
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
|
Phase 2 | |
| RCKT |
$15.44
-0.66 -4.10%
|
RP-L102
Fanconi Anemia (FA)
|
Phase 1 | |
| PDSB |
$2.51
-0.26 -9.39%
|
PDS0101
Head and neck cancer / human papillomavirus-16 (HPV16) infection
|
Phase 1 | |
| SNSS |
$0.47
+-0.44%
|
Vecabrutinib (SNS-062)
Advanced B-Cell Malignancies
|
Phase 1/2 | |
| KURA |
$15.63
+0.05 +0.32%
|
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
|
Phase 2 | |
| BGNE |
$196.31
+4.59 +2.39%
|
Zanubrutinib (BGB-3111) - SEQUOIA
First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
|
Phase 3 | |
| APTO |
$2.47
-0.1 -3.70%
|
CG-806
Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL)
|
Phase 1 | |
| AUTL |
$11.50
-0.74 -6.05%
|
AUTO3 - (AMELIA)
Acute Lymphoblastic Leukemia
|
Phase 1/2 | |
| BPMC |
$71.11
+0.14 +0.20%
|
Avapritinib BLU-285 - PIONEER
Indolent and smoldering systemic mastocytosis (SM)
|
Phase 2 | |
| LLY |
$113.17
+0.37 +0.33%
|
LOXO-305
Refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkin’s lymphomas (NHL)
|
Phase 1/2 | |
| IMV |
$2.59
-0.07 -2.64%
|
DPX-Survivac and pembrolizumab
Diffuse Large Cell Lymphoma
|
Phase 2 | |
| BLUE |
$76.25
+3.29 +4.51%
|
LentiGlobin - HGB-212 Northstar-3
TDT and the β0/β0genotype
|
Phase 3 | |
| MGTA |
$10.48
-0.32 -2.96%
|
MGTA-456
Acute Lymphoblastic Leukemia
|
Phase 2 | |
| CYAD |
$8.98
+0.08 +0.89%
|
CYAD-01 - THINK
Various cancers - solid and hematologic cancers
|
Phase 1/2 | |
| ACHN |
$6.34
-0.01 -0.16%
|
Danicopan (ACH-4471)
Paroxysmal nocturnal hemoglobinuria (PNH)
|
Phase 2 | |
| ALXN |
$109.44
+0.43 +0.39%
|
Danicopan (ACH-4471)
Paroxysmal nocturnal hemoglobinuria (PNH)
|
Phase 2 | |
| AGIO |
$33.99
+1.56 +4.81%
|
AG-348 - Mitapivat (DRIVE)
Pyruvate Kinase Deficiency
|
Phase 2 | |
| SGMO |
$9.62
-0.16 -1.64%
|
ST-400
beta-thalassemia
|
Phase 1/2 | |
| ORTX |
$11.67
-0.32 -2.67%
|
OTL-203
MPS I
|
Phase 1/2 | |
| GMAB |
$22.01
-0.15 -0.68%
|
GEN3013 (DuoBody-CD3xCD20)
B-cell Lymphoma
|
Phase 1/2 | |
| GMDA |
$4.95
-0.01 -0.20%
|
NAM-NK (GDA-201)
Non-Hodgkin lymphoma; Multiple myeloma
|
Phase 1 | |
| BLUE |
$76.25
+3.29 +4.51%
|
bb21217
Multiple Myeloma
|
Phase 1 | |
| CELG |
$110.00
+0.43 +0.39%
|
bb21217
Multiple Myeloma
|
Phase 1 | |
| AGIO |
$33.99
+1.56 +4.81%
|
Ivosidenib and azacitidine ( Vidaza)
Newly diagnosed AML with an IDH1 mutation
|
Phase 1 | |
| ONTX |
$0.39
-0.03 -6.29%
|
Oral Rigosertib and azacitidine
First-line HR-MDS (high risk myelodysplastic syndromes)
|
Phase 3 | |
| FTSV |
$9.65
+1.1 +12.87%
|
5F9 + Azacitidine
Acute myeloid leukemia (AML)
|
Phase 1 | |
| IMGN |
$3.22
-0.03 -0.92%
|
IMGN632
Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)
|
Phase 1 | |
| CRIS |
$1.36
-0.1 -6.85%
|
CA-4948
Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
| ARQL |
$7.89
+0.19 +2.47%
|
ARQ 531
B-cell malignancies
|
Phase 1 | |
| XNCR |
$34.77
+0.86 +2.55%
|
XmAb13676
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
|
Phase 1 | |
| BLUE |
$76.25
+3.29 +4.51%
|
LentiGlobin - HGB-207 Northstar-2
non-β0/β0 transfusion-dependent thalassemia (TDT)
|
Phase 3 | |
| MGNX |
$8.25
+0.3 +3.84%
|
Flotetuzumab
AML/MDS
|
Phase 1 | |
| CNST |
$32.34
-2.04 -5.93%
|
CPI-0610 and ruxolitinib
Myelofibrosis
|
Phase 2 | |
| STML |
$9.60
-0.15 -1.54%
|
SL-401 (Elzonris)
Myelofibrosis (MF)
|
Phase 2 | |
| CTIC |
$0.75
+0.15%
|
Pacritinib - PACIFICA
Myelofibrosis
|
Phase 3 | |
| GERN |
$1.44
-0.04 -2.70%
|
Imetelstat - IMerge Study
Myelodysplastic syndromes
|
Phase 2/3 | |
| CYAD |
$8.98
+0.08 +0.89%
|
CYAD-01 and chemotherapy (DEPLETHINK)
AML or myelodysplastic syndrome (MDS)
|
Phase 1 | |
| DTIL |
$8.99
+0.48 +5.70%
|
PBCAR0191
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia and R/R non-hodgkin lymphoma
|
Phase 1/2 | |
| CORV |
$2.35
-0.05 -2.08%
|
Brinavess
Atrial fibrillation (AF)
|
PDUFA |
Advisory Committee 12/10/2019; PDUFA 12/24/2019
PDUFA date December 24, 2019. FDA Advisory Committee meeting December 10, 2019.
|
| MGNX |
$8.25
+0.3 +3.84%
|
Margetuximab SOPHIA study
Metastatic breast cancer
|
Phase 3 |
SABCS 2019
Second interim overall survival analysis noted OS 21.6 months vs 19.8 months; HR 0.885; p=0.326. Presentation at SABCS December 10-14, 2019. BLA filing due 4Q 2019.
|
| ZLAB |
$38.59
-0.81 -2.06%
|
Margetuximab SOPHIA study
Metastatic breast cancer
|
Phase 3 |
SABCS 2019
Second interim overall survival analysis noted OS 21.6 months vs 19.8 months; HR 0.885; p=0.326. Presentation at SABCS December 10-14, 2019. BLA filing due 4Q 2019.
|
| GRTS |
$7.35
-0.13 -1.74%
|
GRANITE-001 (GO-004)
Solid tumors
|
Phase 1/2 | |
| BLRX |
$2.50
+0.03 +1.21%
|
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
|
Phase 2 | |
| SGEN |
$110.64
+2.34 +2.16%
|
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial
HER2+ Metastatic Breast Cancer (MBC)
|
Phase 2 | |
| GTHX |
$22.98
-0.02 -0.09%
|
Lerociclib (G1T38) plus Faslodex
ER+ breast cancer
|
Phase 1b | |
| GRTS |
$7.35
-0.13 -1.74%
|
SLATE-001
Solid tumors
|
Phase 1 | |
| BLRX |
$2.50
+0.03 +1.21%
|
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
|
Phase 2a | |
| ATNX |
$11.71
+0.32 +2.81%
|
Oraxol
Metastatic breast cancer
|
Phase 3 | |
| AMGN |
$221.31
+0.61 +0.28%
|
ABP 710
REMICADE biosimilar - rheumatoid arthritis
|
PDUFA | |
| AVDL |
$5.00
+0.1 +2.04%
|
AV001
Hospital product
|
PDUFA | |
| PFE |
$36.97
+0.04 +0.11%
|
XTANDI (ARCHES)
Metastatic hormone sensitive prostate cancer
|
PDUFA priority review |
4Q 2019
PDUFA date under priority review 4Q 2019.
|
| BHC |
$27.01
+0.49 +1.85%
|
IDP-123
Psoriasis
|
PDUFA | |
| ITCI |
$9.17
-0.13 -1.40%
|
Lumateperone
Schizophrenia
|
PDUFA | |
| NVO |
$57.09
-0.2 -0.35%
|
PYY 1562
Obesity
|
Phase 1 |
4Q 2019
Phase 1 data due 4Q 2019.
|
| CCXI |
$9.63
+0.26 +2.77%
|
Avacopan - CCX168 (ADVOCATE)
Associated vasculitis (AAV)
|
Phase 3 |
4Q 2019
Phase 3 data due 4Q 2019.
|
| BIIB |
$291.40
-2.74 -0.93%
|
BIIB092 - Anti Tau
Progressive supranuclear palsy (PSP)
|
Phase 2 |
2H 2019
Phase 2 data due 2H 2019.
|
| AXSM |
$24.57
-0.5 -1.99%
|
AXS-05 -GEMINI
Major Depressive Disorder
|
Phase 3 |
4Q 2019
Phase 3 data due 4Q 2019.
|
| VTGN |
$1.07
-0.03 -2.73%
|
AV-101
Healthy volunteers
|
Phase 1b |
2H 2019
Phase 1b data due 2H 2019.
|
| IONS |
$56.98
+0.33 +0.58%
|
IONIS-FXIRx
End-stage renal disease
|
Phase 2b |
2019
Phase 2b data likely due 2019.
|
| RUBY |
$10.06
-0.89 -8.13%
|
RTX-134
Phenylketonuria (PKU)
|
Phase 1/2 |
2H 2019
Phase 1b/2 initial data due 2H 2019.
|
| SPPI |
$8.10
-0.79 -8.89%
|
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
|
Phase 2 |
December 2019
Phase 2 top-line data from Cohort 1 due December 2019. Cohort 2 data due mid-2020.
|
| SLGL |
$9.09
+0.34 +3.85%
|
TWIN
Acne
|
Phase 3 |
4Q 2019
Phase 3 data due 4Q 2019.
|
| RGNX |
$38.17
-0.34 -0.90%
|
RGX-121
MPS II
|
Phase 1/2 |
YE 2019
Phase 1/2 update due at the end of 2019.
|
| CYCC |
$0.39
+0.02 +4.81%
|
CYC140
Leukemias
|
Phase 1 |
2019
Phase 1 initial data due 2019.
|
| GSK |
$44.52
+0.26 +0.59%
|
Mepolizumab
Severe hypereosinophilic syndrome (HES)
|
Phase 3 |
2H 2019
Phase 3 data due 2H 2019.
|
| GILD |
$64.32
-0.32 -0.50%
|
Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS
Nonalcoholic steatohepatitis (NASH)
|
Phase 2 |
4Q 2019
Phase 2b 48-week data due 4Q 2019.
|
| ARQL |
$7.89
+0.19 +2.47%
|
Miransertib - ARQ 092
Solid tumors
|
Phase 1b |
2H 2019
Phase 1b data due 2H 2019.
|
| HEPA |
$3.04
-0.03 -0.98%
|
CRV431
Hepatitis B
|
Phase 1 |
4Q 2019
MAD trial commencement of dosing announced August 14, 2019 with data due 4Q 2019.
|
| TRIL |
$0.27
+-1.80%
|
TTI-622
Refractory lymphoma or multiple myeloma
|
Phase 1b |
Late-2019
Phase 1a/b preliminary data due late-2019.
|
| BMRN |
$75.88
+0.55 +0.73%
|
Vosoritide
Achondroplasia - young children
|
Phase 2 |
YE 2019
Phase 3 top-line data due end of 2019.
|
| BGNE |
$196.31
+4.59 +2.39%
|
Tislelizumab
Hepatocellular carcinoma (HCC) - second-line
|
Phase 2 |
2019
Phase 2 data due 2019 or early 2020.
|
| KMDA |
$5.49
+0.14 +2.67%
|
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
|
Phase 1/2 |
YE 2019
Phase 2 top-line data due YE 2019.
|
| KRTX |
$17.01
-0.24 -1.39%
|
KarXT
Acute psychosis in patients with schizophrenia
|
Phase 2 |
Late-2019
Phase 2 top-line data due late-2019.
|
| BVXV |
$5.77
-0.22 -3.67%
|
M-001
Universal flu vaccine
|
Phase 2 |
YE 2019
Phase 2 data due by the end of 2019.
|
| ALDX |
$6.09
+0.07 +1.25%
|
ADX-102 - topical ocular reproxalap - RENEW
Dry eye syndrome
|
Phase 3 |
4Q 2019
Phase 3 (Part 1) to be completed 4Q 2019.
|
| GSK |
$44.52
+0.26 +0.59%
|
TSR-042 - GARNET
Endometrial cancer
|
Phase 1 |
2H 2019
Phase 1 pivotal data and BLA filing due 2H 2019.
|
The public FDA Calendar is limited to 150 events in chronological order. The full calendar of approximately 800 events is available to PREMIUM MEMBERS which you can access through our 14-day FREE TRIAL.